Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer

23-04-2024 | Breast Cancer | Special Feature

Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy

Author: Tetsuhiro Yoshinami

Published in: Breast Cancer

Login to get access

Abstract

Circulating tumor DNA (ctDNA) consists of DNA fragments released from cancer cells into the blood circulation with quick clearance. Analysis of ctDNA can enable real-time assessment of the presence of cancer cells and their genomic characteristics. Therefore, ctDNA is expected to be one of the most useful biomarkers for cancer. In recent years, several ultra-sensitive assays for ctDNA analysis have been developed, and many clinical trials are using these assays to investigate the efficacy of ctDNA-based therapeutic strategies. In the perioperative phase, real-time identification of minimal residual disease at the molecular level with ctDNA analysis can help evaluate the risk of recurrence to inform escalation or de-escalation of perioperative drug therapy. Many trials have examined whether therapeutic strategies using ctDNA analysis to predict treatment efficacy or resistance to molecular targeted agents can improve prognosis in metastatic breast cancer. In this review, we discuss the most recent ctDNA assays, the significance of introducing ctDNA assays to clinical practice, and the research on their application in perioperative and metastatic phases.
Literature
1.
Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9(1):5068.PubMedPubMedCentralCrossRef
2.
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–38.PubMedCrossRef
3.
4.
Corcoran RB, Chabner BA. Application of dell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379(18):1754–65.PubMedCrossRef
5.
Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts RJ, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 2019;5(10):1473–8.PubMedPubMedCentralCrossRef
6.
Yoshinami T, Kagara N, Motooka D, Nakamura S, Miyake T, Tanei T, et al. Detection of ctDNA with personalized molecular barcode NGS and its clinical significance in patients with early breast cancer. Transl Oncol. 2020;13(8): 100787.PubMedPubMedCentralCrossRef
7.
Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–72.PubMedPubMedCentralCrossRef
8.
Medford AJ, Moy B, Spring LM, Hurvitz SA, Turner NC, Bardia A. Molecular residual disease in breast cancer: detection and therapeutic interception. Clin Cancer Res. 2023;29(22):4540–8.PubMedCrossRef
9.
Vlataki K, Antonouli S, Kalyvioti C, Lampri E, Kamina S, Mauri D, et al. Circulating tumor DNA in the management of early-stage breast cancer. Cells. 2023;12(12):1573.PubMedPubMedCentralCrossRef
10.
Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255–63.PubMedCrossRef
11.
Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, et al. Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. J Clin Oncol. 2022;40(22):2408–19.PubMedPubMedCentralCrossRef
12.
Gydush G, Nguyen E, Bae JH, Blewett T, Rhoades J, Reed SC, et al. Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. Nat Biomed Eng. 2022;6(3):257–66.PubMedPubMedCentralCrossRef
13.
Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin Cancer Res. 2020;26(11):2556–64.PubMedPubMedCentralCrossRef
14.
Chen S, Quinn K, Lee CY, Zhao J, Chang K, Jiang T, et al. A method for quantifying circulating tumor DNA level and molecular response using methylome sequencing. Cancer Res. 2023;83(7_suppl):3123.CrossRef
15.
Jiang T, Wu I, Kim Y, Alla N, Tran G, Ma D, et al. Analytical validation of a robust integrated genomic and epigenomic liquid biopsy for biomarker discovery, therapy selection, and response monitoring. Cancer Res. 2023;83(7_suppl):6601.CrossRef
16.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.PubMedCrossRef
17.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.PubMedCrossRef
18.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.CrossRef
19.
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41(6):1091-1102.e4.PubMedCrossRef
20.
Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023;4(1):128–47.PubMed
21.
Alix-Panabieres C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858–73.PubMedCrossRef
22.
O’Sullivan CC, Clarke R, Goetz MP, Robertson J. Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review. JAMA Oncol. 2023;9(9):1273–82.PubMedCrossRef
23.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.PubMedCrossRef
24.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–72.PubMedCrossRef
25.
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–15.PubMedCrossRef
26.
Prat A, Chaudhury A, Solovieff N, Pare L, Martinez D, Chic N, et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies. J Clin Oncol. 2021;39(13):1458–67.PubMedPubMedCentralCrossRef
27.
Prat A, Brasó-Maristany F, Martínez-Sáez O, Sanfeliu E, Xia Y, Bellet M, et al. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nat Commun. 2023;14(1):1157.PubMedPubMedCentralCrossRef
28.
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246–56.PubMedPubMedCentralCrossRef
29.
O’Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390–403.PubMedPubMedCentralCrossRef
30.
Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, et al. Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. Clin Cancer Res 2023; Epub ahead of print.
31.
Burstein HJ, DeMichele A, Somerfield MR, Henry NL, Biomarker T. Targeted therapy in metastatic breast cancer expert panels. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023;41(18):3423–5.PubMedCrossRef
32.
Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2019;30(3):365–73.PubMedCrossRef
33.
Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(27):3205–21.PubMedCrossRef
34.
Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.PubMedCrossRef
35.
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489–98.PubMedCrossRef
36.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058–70.PubMedCrossRef
37.
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49.PubMedCrossRef
38.
Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al. Randomized Phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023;41(24):4004–13.PubMedCrossRef
39.
Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, et al. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol. 2007;25(24):3572–5.PubMedCrossRef
40.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bieche I, et al. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open. 2022;12(3): e055821.PubMedPubMedCentralCrossRef
41.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte RT, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23(11):1367–77.PubMedCrossRef
42.
Hafner M, Mills CE, Subramanian K, Chen C, Chung M, Boswell SA, et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol. 2019;26(8):1067-1080.e8.PubMedPubMedCentralCrossRef
43.
Hendrychova D, Jorda R, Krystof V. How selective are clinical CDK4/6 inhibitors? Med Res Rev. 2021;41(3):1578–98.PubMedCrossRef
44.
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, et al. Palbociclib after CDK4/6i and endocrine therapy (PACE): a randomized phase II Study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer. Cancer Res. 2023;83(5_suppl):GS3-06.CrossRef
45.
O’Leary B. PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching. Nat Rev Clin Oncol. 2023;20(2):67–8.PubMedCrossRef
Metadata
Title
Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy
Author
Tetsuhiro Yoshinami
Publication date
23-04-2024
Publisher
Springer Nature Singapore
Published in
Breast Cancer
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-024-01571-9
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits